TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06846320: Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Sponsor: AbbVie · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 315 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT06846320 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06846320 Rescue Dossier →